دورة المؤشرنت للتحليل الفني
50 دينار كويتي
أنت تستخدم أحد المتصفحات القديمة. قد لا يتم عرض هذا الموقع أو المواقع الأخرى بشكل صحيح.
يجب عليك ترقية متصفحك أو استخدام أحد المتصفحات البديلة.
يجب عليك ترقية متصفحك أو استخدام أحد المتصفحات البديلة.
cima
- بادئ الموضوع NWAAF_10
- تاريخ البدء
أبو وليد
عضو نشط
- التسجيل
- 9 نوفمبر 2001
- المشاركات
- 147
CIMA تشتري أسهمها ...لماذا؟
CIMA LABS Commences Share Repurchasing Under Existing Buy-Back Authorization
MONDAY, NOVEMBER 05, 2001 8:11 AM
- BusinessWire
CIMA LABS Commences Share Repurchasing Under Existing Buy-Back Authorization
11/5/2001 8:11:00 AM
MINNEAPOLIS, Nov 5, 2001 (BUSINESS WIRE) -- CIMA LABS INC. (CIMA) today announced that it has commenced repurchasing its common stock on the open market under an existing plan whereby the Company can buy back up to $20 million of its shares.
John M. Siebert, Ph.D., president and chief executive officer, said, "Reflecting CIMA's positive business outlook, we believe our stock represents an excellent value at current price levels. Our Board of Directors and senior management view this repurchasing activity as an expression of confidence in CIMA's future."
About CIMA
CIMA develops and manufactures prescription and over-the-counter products for pharmaceutical companies based upon its proprietary, fast-dissolve drug delivery technologies, OraSolv(R) and DuraSolv(TM). CIMA formulates a pharmaceutical company's active drug ingredient into a new, orally disintegrating dosage form that dissolves quickly in the mouth without chewing or the need for water. Taste masking agents may be used with the Company's fast-dissolve technologies to prevent or minimize the unpleasant taste associated with many active drug ingredients. CIMA currently manufactures five pharmaceutical brands utilizing its OraSolv and DuraSolv technologies: three prescription and two over-the-counter.
The statements in this press release regarding the repurchase of CIMA common stock and CIMA's positive outlook, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. A number of factors could cause actual results to differ materially from CIMA's assumptions and expectations. CIMA may repurchase up to $20 million of its common stock, or any lesser amount, depending on the trading price of its common stock, market conditions, or for other reasons. Additional factors that may cause actual results to differ from CIMA's assumptions and expectations include those set forth under the heading "Factors That Could Affect Future Results" included in CIMA's most recent SEC filings. All forward-looking statements are qualified by, and should be considered in conjunction with, such cautionary statements.
CIMA LABS Commences Share Repurchasing Under Existing Buy-Back Authorization
MONDAY, NOVEMBER 05, 2001 8:11 AM
- BusinessWire
CIMA LABS Commences Share Repurchasing Under Existing Buy-Back Authorization
11/5/2001 8:11:00 AM
MINNEAPOLIS, Nov 5, 2001 (BUSINESS WIRE) -- CIMA LABS INC. (CIMA) today announced that it has commenced repurchasing its common stock on the open market under an existing plan whereby the Company can buy back up to $20 million of its shares.
John M. Siebert, Ph.D., president and chief executive officer, said, "Reflecting CIMA's positive business outlook, we believe our stock represents an excellent value at current price levels. Our Board of Directors and senior management view this repurchasing activity as an expression of confidence in CIMA's future."
About CIMA
CIMA develops and manufactures prescription and over-the-counter products for pharmaceutical companies based upon its proprietary, fast-dissolve drug delivery technologies, OraSolv(R) and DuraSolv(TM). CIMA formulates a pharmaceutical company's active drug ingredient into a new, orally disintegrating dosage form that dissolves quickly in the mouth without chewing or the need for water. Taste masking agents may be used with the Company's fast-dissolve technologies to prevent or minimize the unpleasant taste associated with many active drug ingredients. CIMA currently manufactures five pharmaceutical brands utilizing its OraSolv and DuraSolv technologies: three prescription and two over-the-counter.
The statements in this press release regarding the repurchase of CIMA common stock and CIMA's positive outlook, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. A number of factors could cause actual results to differ materially from CIMA's assumptions and expectations. CIMA may repurchase up to $20 million of its common stock, or any lesser amount, depending on the trading price of its common stock, market conditions, or for other reasons. Additional factors that may cause actual results to differ from CIMA's assumptions and expectations include those set forth under the heading "Factors That Could Affect Future Results" included in CIMA's most recent SEC filings. All forward-looking statements are qualified by, and should be considered in conjunction with, such cautionary statements.
NWAAF_10
عضو نشط
- التسجيل
- 1 أكتوبر 2001
- المشاركات
- 167
الأخ أبوالوليد
الشركة من 5 نوفمبر أعادة شراء أسهمها بالمبلغ المذكور في التقرير لتحافظ على قيمة السهم فاسهم سيما قد إنحفظ بصورة سريعة من 54 إلى 36 وتوقف عند 31 $ تقريبا وهي أسهم أحتفظ مع وضع ستوب لوز
وهي مرتفعة اليوم تقريبا 4% شركة صناعات صيدلانية والأخ خالد تكلم عنها في رابط سابق
الشركة من 5 نوفمبر أعادة شراء أسهمها بالمبلغ المذكور في التقرير لتحافظ على قيمة السهم فاسهم سيما قد إنحفظ بصورة سريعة من 54 إلى 36 وتوقف عند 31 $ تقريبا وهي أسهم أحتفظ مع وضع ستوب لوز
وهي مرتفعة اليوم تقريبا 4% شركة صناعات صيدلانية والأخ خالد تكلم عنها في رابط سابق
دورة المؤشرنت للتحليل الفني
50 دينار كويتي